Teva Pharmaceuticals
TEVA
631 hedge funds and large institutions have $21.4B invested in Teva Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 136 funds opening new positions, 205 increasing their positions, 188 reducing their positions, and 45 closing their positions.
202% more first-time investments, than exits
New positions opened: 136 | Existing positions closed: 45
64% more call options, than puts
Call options by funds: $1.1B | Put options by funds: $673M
62% more capital invested
Capital invested by funds: $13.3B → $21.4B (+$8.18B)
41% more funds holding in top 10
Funds holding in top 10: 27 → 38 (+11)
15% more funds holding
Funds holding: 551 → 631 (+80)
2.61% more ownership
Funds ownership: 57.3% → 59.91% (+2.6%)
9% more repeat investments, than reductions
Existing positions increased: 205 | Existing positions reduced: 188
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM Investment Management
Laguna Beach,
California
|
+$339M |
| 2 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$179M |
| 3 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$146M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
+$132M |
| 5 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
+$119M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
PointState Capital
New York
|
-$417M |
| 2 |
DFO
Duquesne Family Office
New York
|
-$264M |
| 3 |
SPC
Slate Path Capital
New York
|
-$160M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$152M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$122M |
TEVA Hedge Fund Activity: Q4 2025 in Review
631 institutional investors reported a position in Teva Pharmaceuticals (TEVA) for Q4 2025, worth a combined $21.4B — up 62% from $13.3B a quarter earlier.
Buyers outnumbered sellers: 136 funds opened new TEVA positions and 45 closed out — a net gain of 91 holders — while 205 added to existing stakes and 188 trimmed.
The largest buyer was WCM Investment Management, adding an estimated $339M. The largest seller was PointState Capital, cutting an estimated $417M.
- 631 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2025, up from 551 in Q3 2025.
- Funds reported $21.4B of Teva Pharmaceuticals stock for Q4 2025, up 62% quarter-over-quarter.
- 136 funds opened new Teva Pharmaceuticals positions in Q4 2025 and 45 closed out, a net change of +91 holders.
- The largest Teva Pharmaceuticals buyer in Q4 2025 was WCM Investment Management, an estimated $339M added.
- The largest Teva Pharmaceuticals seller in Q4 2025 was PointState Capital, an estimated $417M sold.
Based on aggregated 13F filings for Q4 2025.